<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 14, 2020 (HealthDay News) — By treating or preventing infection, glecaprevir and pibrentasvir (G\/P) regimens are promising for increasing access to the transplantation of kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+\/R\u2212), according to two studies recently published in the Journal of the American Society of Nephrology<\/i> and Annals of Internal Medicine<\/i>.<\/p>\n
Meghan E. Sise, M.D., from Massachusetts General Hospital in Boston, and colleagues enrolled 63 patients without HCV infection of whom 30 underwent kidney transplantation from an HCV-viremic deceased donor followed by eight weeks of once-daily G\/P. The researchers found that all recipients achieved a sustained virologic response. There were no serious adverse events deemed likely to be related to HCV infection or treatment with G\/P.<\/p>\n
Christine M. Durand, M.D., from Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a single-center, open-label trial involving HCV D+\/R\u2212 patients. Participants received one dose of G\/P before organ perfusion and once-daily treatment for four weeks. Ten kidney transplants were performed. The researchers found no recipient deaths during a median 12 months of follow-up. After day 7, HCV RNA was undetectable in all recipients. At any time point, none of the recipients had grade 3 or higher treatment-related adverse events or aminotransferase or bilirubin levels 2.5 times the upper limit of normal or greater.<\/p>\n
“In all 10 HCV D+\/R\u2212 kidney transplants, four-week G\/P prophylaxis prevented HCV without treatment-related adverse events or substantial liver enzyme abnormalities,” the authors write.<\/p>\n
Several authors from both studies disclosed ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text — Sise (subscription or payment may be required)<\/a><\/p>\n Abstract\/Full Text — Durand (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n